Overview

Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
0
Participant gender:
All
Summary
This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Dong-A ST Co., Ltd.
Treatments:
Udenafil
Criteria
Inclusion Criteria:

- Patients who completed the initial study(DA8159_PAH_II), 12-week, double-blind,
placebo-controlled trial

Exclusion Criteria:

-